Overview

A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors

Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2029-01-01
Target enrollment:
Participant gender:
Summary
To learn if KSQ-001EX is safe to give to participants with advanced forms of solid tumors.
Phase:
PHASE1
Details
Lead Sponsor:
M.D. Anderson Cancer Center
Collaborator:
KSQ Therapeutics, Inc.
Treatments:
Cyclophosphamide
fludarabine
Interleukin-2